Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of

Yujiro Matsuishi1,2,3, Bryan J Mathis4, Nobutake Shimojo1

  • 1Department of Emergency and Critical Care Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.

Biomedicines
|April 3, 2021
PubMed

Insights

COVID-19 can cause severe organ damage through endothelial dysfunction, leading to conditions like ARDS and multi-organ failure. Therapies targeting endothelial function may improve patient outcomes.

Area of Science:

  • Cardiovascular Science
  • Infectious Diseases
  • Pathology

Background:

  • The COVID-19 pandemic has highlighted severe health complications beyond respiratory issues.
  • Endothelial dysfunction is implicated in the exacerbation of COVID-19 by chronic conditions like diabetes and cardiovascular disease.
  • Excessive inflammation in COVID-19 contributes to acute respiratory distress syndrome (ARDS) and multi-organ dysfunction syndrome (MODS).

Purpose of the Study:

  • To review the impact of immune-mediated endothelial dysfunction on organ injuries in COVID-19 patients.
  • To discuss the mechanisms leading to multi-organ dysfunction in severe COVID-19.
  • To explore potential therapeutic strategies targeting endothelial dysfunction and bradykinin storm.

Main Methods:

  • Literature review and synthesis of existing research on COVID-19 pathophysiology.
  • Analysis of studies detailing organ-specific injuries (heart, brain, kidney, liver) in COVID-19.
  • Discussion of pharmacological interventions for endothelial dysfunction.

Main Results:

  • COVID-19 is associated with significant heart injuries, ischemic stroke, hemorrhage, acute kidney injury, and liver injury.
  • Immune-mediated endothelial dysfunction is a key factor in the development of multi-organ dysfunction syndrome in COVID-19.
  • Excessive inflammation, thrombosis, and disseminated intravascular coagulation (DIC) contribute to mortality.

Conclusions:

  • Maintaining endothelial integrity is critical for improving prognosis in COVID-19 patients.
  • Therapeutic interventions aimed at improving endothelial function show promise.
  • Angiotensin receptor blockers and ACE inhibitors may offer benefits by addressing endothelial dysfunction and bradykinin storm.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
73
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
90
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
278
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
139
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
81
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
58